Table 2.
The clinical trials of DC vaccines in ovarian cancer.
| Published Year | Multiple arms of the trial | NO. | Phase of study | Clinical effect | |
|---|---|---|---|---|---|
| Response of DC treatment | Survival period | ||||
| 2000 ( 52 ) | Single arm | 3* | I/II | 2 SD and 1 PD after 3 doses | – |
| 2012 ( 53 ) | Arm1 (n=5): DC vaccine; Arm2 (n=6): Cyclophosphamide + DC vaccine |
11 | I/II | 6 NED; 3 recurrence at 6-26 months; 2 recurrence during vaccination |
In arms 1,2: estimated 3-year PFS: 40% vs 80%; estimated 3-year OS: 80% vs 100% |
| 2012 ( 16 ) | Arm1 (n=14): wild type p53 peptide; Arm2 (n=7): DC vaccines loaded with p53 peptide |
21 | II | Arm1: 2 NED, 9 RD; Arm2: 2 NED, 5 RD |
For arms 1/2: median PFS: 4.2 months vs 8.7 months; median OS: 40.8 months vs 29.6 months |
| 2014 ( 55 ) | – | 56 | retrospective study | 1 PR, 7SD, 42 PD, 7 NE | Median OS: 14.5 months |
| 2014 ( 54 ) | – | 28 | II | 1 CR, 1 PR, 2 SD, 24 PD | – |
| 2019 ( 51 ) | – | 3* | I/II | 2 SD, 1 PD | Median OS: 13.1 months |
| 2020 | – | 1 | Case report | – | OS since the 1st dose: 15 months |
| 2013 ( 58 ) | – | 5 | I | 2PD, 2SD, 1 mixed response | PFS: 1 patient 36 months, 1 patient 44 months |
| 2013 ( 59 ) | UPCC 11807 (n=6): DC vaccine + bev + cyclophosphamide; UPCC 10808 (n=3): DC vaccine + lymphodepletion + autologous vaccine-primed T cells |
9 | I | UPCC 11807: 2 PR, 2 SD, 1 NED, 1 PD then PR; UPCC 11808: 1 CR, 1PD, 1 SD |
– |
| 2014 ( 60 ) | – | 7* | II | 1 PR, 2 SD, 4 PD | Median PFS: 176 days median OS: 198 days |
| 2018 ( 17 ) | Cohort 1 (n=5): DC vaccine; Cohort 2 (n=10): DC vaccine + Bev; Cohort 3 (n=10): DC vaccine + Bev + cyclophosphamide |
25 | I | Cohort 1: 3 SD, 2 PD; Cohort 2: 1 PR, 4 SD, 5 PD; Cohort 3: 1 PR, 5 SD, 4 PD |
In cohort 2, median OS: 11 months; In cohort 3: median OS > 25 months; |
| 2002 ( 61 ) | – | 6* | I | 4 SD for 14-45 weeks; 2 PD after 4-8 doses | – |
| 2015 ( 62 ) | 14 consecutive IL-2 injections | 10 | I/II | 5 CR, 2 SD, 3 PD |
Median PFS: 19.2 months; median OS: 43.8 months OS: 64.95 ± 7.62 months |
| 2006 ( 71 ) | – | 4* | I/II | 2-9 months treatment period | – |
| 2007 ( 70 ) | – | 1 | Case report | PR | – |
| 2013 ( 56 ) | – | 2 | Case report | 2 PD | PFS: 0, 2 months OS: 70, 64 months |
OC, ovarian cancer; SD, stable disease; PD, progressive disease; RD, recurrent disease; doses, doses of DC vaccinations; NED, no evidence of disease; PFS, progression free survival; OS, overall survival; TILs, tumor infiltrating lymphocytes; Bev, bevacizumab; Treg, regulatory T cells.
*Only the data of ovarian cancer patients are shown here, these clinical studies include more than one type of cancer disease.